Masimo, a developer of noninvasive monitoring technologies, has received approval from the Japanese Ministry of Health Labor & Welfare (MHLW) and Health Canada for its Pronto-7.
Pronto-7 is a palm-sized, handheld device which aids clinicians to noninvasively measure total hemoglobin (SpHb), SpO2, perfusion index, and pulse rate in less than one minute.
Masimo SpHb provides immediate real-time hemoglobin results and facilitates clinicians to assess patients and detect and treat internal bleeding and low hemoglobin conditions earlier.
In addition to Normal Mode, Pronto-7 offers Max Sensitivity Mode that allows measurement over a broader range of patients and three noninvasive sensor sizes to accommodate the range of finger diameters.
Each sensor is color-coded to make size identification easy (Small-Yellow, Medium-Red, and Large-White) and optimized to improve performance in low ambient temperatures.
Masimo founder and CEO Joe Kiani said they believe that the Pronto-7 will help clinicians to better assess more patients and make better clinical decisions based on the availability of quick and noninvasive hemoglobin measurement.
Masimo Pronto-7 is pending FDA 510(k) clearance in the US.